Literature DB >> 24291896

[Clinical and histopathological features of myositis associated with anti-mitochondrial antibodies].

Jun Shimizu1.   

Abstract

Anti-mitochondrial antibodies (AMA) are known to be characteristic markers of primary biliary cirrhosis (PBC). The association of PBC with myositis has been reported mainly as case reports, and comprehensive studies of the clinical and histopathological features of patients with myositis and AMAs or PBC have not been conducted thus far. We retrospectively reviewed 212 patients with inflammatory myopathies in our laboratory and found 24 patients with AMA-positive myositis (11%) (seven patients with PBC and 17 patients without PBC). The analysis of clinical and histopathological features revealed that myositis associated with AMAs frequently include patients with a clinically chronic disease course, muscle atrophy, cardiopulmonary involvement and granulomatous inflammation, regardless of the presence or absence of PBC. We also reviewed and analyzed the clinical features of previously reported patients. The analysis of 75 patients, which have been described in previous case reports including the ones of meeting abstracts, also showed the similar results about clinical features of myositis associated with AMAs and supported our findings. Our study suggests that myositis associated with AMAs form a characteristic subgroup.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24291896     DOI: 10.5692/clinicalneurol.53.1114

Source DB:  PubMed          Journal:  Rinsho Shinkeigaku        ISSN: 0009-918X


  2 in total

1.  Associations between anti-mitochondrial antibodies and cardiac involvement in idiopathic inflammatory myopathy patients : A systematic review and meta-analysis.

Authors:  Hui Wang; Yuan Zhu; Jingjing Hu; Jieni Jin; Jun Lu; Cong Shen; Zhaobin Cai
Journal:  Z Rheumatol       Date:  2022-05-16       Impact factor: 1.372

2.  Anti-mitochondrial M2 Antibodies Enhance the Risk of Supraventricular Arrhythmias in Patients with Elevated Hepatobiliary Enzyme Levels.

Authors:  Hiroki Konishi; Koji Fukuzawa; Shumpei Mori; Seimi Satomi-Kobayashi; Kunihiko Kiuchi; Atsushi Suzuki; Yoshihiko Yano; Akihiro Yoshida; Ken-Ichi Hirata
Journal:  Intern Med       Date:  2017-07-15       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.